Development of an in silico model for predicting efflux substrates in Caco-2 cells

International Journal of Pharmaceutics

Volumn 343, Issue 1-2, 2007, Pages 98-105

  Zhang, Litai ^a   Balimane, Praveen V ^a   Johnson, Stephen R ^a   Chong, Saeho ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Caco 2 cell; Drug discovery; Efflux; In silico model; P gp substrates

Indexed keywords

DEXAMETHASONE; DIGOXIN; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; INDOMETACIN; MANNITOL; METHOTREXATE; METOPROLOL; PACLITAXEL; PROBENECID; RHODAMINE 123; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; VALIDATION STUDY;

CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 34548253572     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.05.017     Document Type: Article

References (32)

1. Adachi Y., Suzuki H., and Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-gp. Pharm. Res. 18 (2001) 1660-1668
2. Balimane B.V., Han Y.-H., and Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS 8 (2006) E1-E13
3. Balimane P.V., Patel K., Marino A., and Chong S. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur. J. Pharm. Biopharm. 58 (2004) 99-105
4. Breiman, L., Friedman, J.H., Olshen, R.A., Stone, a.C.J., 1984. Classification and Regression Trees.
5. Cianchetta G., Singleton R.W., Zhang M., Wildgoose M., Giesing D., Fravolini A., Cruciani G., and Vaz R.J. A Pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J. Med. Chem. 48 (2005) 2927-2935
6. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E.G., Lan L.-B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., and Wrighton S.A. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61 (2002) 974-981
7. Englund G., Rorsman F., Ronnblom A., Karlbom U., Lazorova L., Grasjo J., Kindmark A., and Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29 (2006) 267-277
8. FDA, 2004. Challenges and Opportunity on the critical path to new medical products. FDA Report.
9. FDA, 2006. Guidance for Industry: Drug interaction studies-Study design, data analysis, and implications for dosing and labeling. FDA Report.
10. Gombar V.K., Polli J.W., Humphreys J.E., Wring S.A., and Serabjit-Singh C.S. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci. 93 (2004) 957-968
11. Hawkins D.M., Young S.S., and Rusinko III A. Analysis of large structure-activity data set using recursive partitioning. Quant. Struct. Act. Relat. 16 (1997) 296-302
12. Kim R. Transporter and xenobiotic disposition. Toxicology 181-182 (2002) 291-297
13. Lin J. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55 (2003) 53-81
14. Lin J., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin. Pharmacokinet. 42 (2003) 59-98
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
16. Marino A., Yarde M., Patel H., Chong S., and Balimane P. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int. J. Pharm. 297 (2005) 235-241
17. Matheny C., Lamb M., Brouwer K., and Pollak G. Pharmacokinetic and pharmacodynamic implications of P-gp modulation. Pharmacotherapy 21 (2001) 778-796
18. Mazzatorta P., Benfenati E., Lorenzini P., and Vighi M. QSAR in ecotoxicity: an overview of modern classification techniques. J. Chem. Inf. Comput. Sci. 44 (2004) 105-112
19. Penzotti J.E., Lamb M.L., Evensen E., and Grootenhuis P.D.J. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem. 45 (2002) 1737-1740
20. Perloff M., Stromer E., von Moltke L., and Greenblatt D. Rapid assessment of P-gp inhibition and induction in vitro. Pharm. Res. 20 (2003) 1177-1183
21. Polli J., Jerrett J., Studenberg J., Humphreys J., Dennis S., Brower K., and Wooley J. Role of P-gp on CNS disposition of amprenavir, an HIV protease inhibitor. Pharm. Res. 16 (1999) 1206-1212
22. Polli J., Wring S., Humphreys J., Huang L., Morgan J., Webster L., and Serabjit-Singh C. Rational use of in vitro P-gp assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 620-628
23. Sababi M., Borga O., and Bengtsson U. The role of P-gp in limiting intestinal absorption of digoxin in rats. Eur. J. Pharm. Sci. 14 (2001) 21-27
24. Seelig A. How does P-glycoprotein recognize its substrates?. Int. J. Clin. Pharmacol. Ther. 36 (1998) 50-54
25. Seithel A., Karlsson J., Hilgendorf C., Bjorquist A., and Ungell A. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28 (2006) 291-299
26. Stouch T.R., and Gudmundsson O. Progress in understanding the structure-activity relationships of [drugs interacting with] P-glycoprotein. Adv. Drug Del. Rev. 54 (2002) 315-328
27. Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
28. van Rhee A.M., Stocker J., Printzenhoff D., Creech C., Wagoner P.K., and Spear K.L. Retrospective analysis of an experimental high-throughput screening data set by recursive partitioning. J. Comb. Chem. 3 (2000) 267-277
29. Wang R.B., Kuo C.L., Lien L.L., and Lien E.J. Structure-activity relationship: Analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. 28 (2003) 203-228
30. Wang Y.-H., Li Y., Yang S.-L., and Yang L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J. Chem. Inform. Model. 45 (2005) 750-757
31. Xue Y., Yap C.W., Sun L.Z., Cao Z.W., Wang J.F., and Chen Y.Z. Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inform. Comp. Sci. 44 (2004) 1497-1505
32. Yamazaki M., Neway W., Ohe T., Chen I., Rowe J., Hochman J., Chiba M., and Lin J. In vitro substrate identification studies for P-gp mediated transport: Species difference and predictability of in vivo results. J. Pharm. Exp. Ther. 296 (2001) 723-735